Pediatric Long-Term Follow-up and Rollover Study
- Conditions
- Diffuse AstrocytomaAnaplastic AstrocytomaAstrocytomaOligodendroglioma, ChildhoodAnaplastic OligodendrogliomaGlioblastomaPilocytic AstrocytomaGiant Cell AstrocytomaPleomorphic XanthoastrocytomaAnaplastic Pleomorphic Xanthoastrocytoma
- Interventions
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 166
- Registration Number
- NCT03975829
- Locations
- 🇺🇸
Phoenix Children s Hospital, Phoenix, Arizona, United States
🇺🇸Childrens National Hospital, Washington, District of Columbia, United States
🇺🇸Nicklaus Childrens Hospital, Miami, Florida, United States
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT03968419
- Locations
- 🇺🇸
University of Kansas Medical Center Neurology Dept., Kansas City, Kansas, United States
🇺🇸Methodist Hospital / Methodist Cancer Center, Houston, Texas, United States
🇺🇸UCLA Oncology Hematology, La Jolla, California, United States
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
- Conditions
- Diffuse Large B-cell LymphomaLarge B-cell LymphomaAcute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- Biological: Rapcabtagene autoleucel single agentDrug: Ibrutinib
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT03960840
- Locations
- 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- Conditions
- Idiopathic Immune-complex-membranoproliferative GlomerulonephritisC3 Glomerulopathy
- Interventions
- Drug: LNP023
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 183
- Registration Number
- NCT03955445
- Locations
- 🇺🇸
University of Iowa Health Care, Iowa City, Iowa, United States
🇺🇸Georgia Nephrology Research Inst, Lawrenceville, Georgia, United States
🇺🇸Col Uni Med Center New York Presby, New York, New York, United States
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
- Conditions
- Age-Related Macular DegenerationWet Macular DegenerationMacular DegenerationRetinal DiseasesEye DiseasesRetinal Degeneration
- Interventions
- Biological: brolucuzumab 6 mg IVT
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT03954626
- Locations
- 🇵🇷
Novartis Investigative Site, Arecibo, Puerto Rico
A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Drug: MBG453Drug: PlaceboDrug: Hypomethylating agents
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 127
- Registration Number
- NCT03946670
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: ZPL389 30mgDrug: ZPL389 50mgDrug: TCS and/or TCI
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 123
- Registration Number
- NCT03948334
- Locations
- 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom
Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients
- Conditions
- Asthma
- Interventions
- Drug: LOU064 100 mgDrug: Placebo
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT03944707
- Locations
- 🇷🇺
Novartis Investigative Site, Ulyanovsk, Russian Federation
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
- Conditions
- High-risk Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT03940352
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
🇺🇸Duke University Medical Center ., Durham, North Carolina, United States
A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT03938454
- Locations
- 🇺🇸
Childrens Hospital Boston, Boston, Massachusetts, United States
🇺🇸University of Pittsburgh ., Pittsburgh, Pennsylvania, United States
🇺🇸Foundation for Sickle Cell Disease Research, Hollywood, Florida, United States